Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumabChristopher Carlson, Jerome Barakos, Wahiba Estergard et al.|Alzheimer s & Dementia|2011Cited by 76
Amyloid‐related imaging abnormalities from trials of solanezumab for Alzheimer's diseaseChristopher Carlson, Jerome Barakos, Eric Siemers et al.|Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring|2016Cited by 65
P4‐472: Vasogenic edema in the setting of ß‐amyloid lowering therapy, adverse event: what is it and how is it detected?Jerome Barakos, Eric Siemers, Joonmi Oh et al.|Alzheimer s & Dementia|2011Cited by 3
[P1–044]: SAFETY OF SOLANEZUMAB IN PHASE 3 STUDIES IN INDIVIDUALS WITH MILD ALZHEIMER's DISEASE DEMENTIAChristopher Carlson, Eric Siemers, Greg Anglin et al.|Alzheimer s & Dementia|2017Cited by 1
[P1–394]: COMPARISON OF BASELINE ARIA‐H PREVALENCE AT 1.5T AND 3T MRI FIELD STRENGTHS IN A MULTI‐SITE GLOBAL CLINICAL TRIAL WITH COHORT OF 2137 AD SUBJECTSAdam J. Schwarz, Eric Siemers, Joonmi Oh et al.|Alzheimer s & Dementia|2017Cited by 1